ResMed Inc. (NYSE:RMD) Shares Acquired by MML Investors Services LLC

MML Investors Services LLC increased its position in shares of ResMed Inc. (NYSE:RMD - Free Report) by 31.9% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 11,468 shares of the medical equipment provider's stock after acquiring an additional 2,771 shares during the quarter. MML Investors Services LLC's holdings in ResMed were worth $2,623,000 as of its most recent SEC filing.

A number of other large investors have also made changes to their positions in RMD. Invesco Ltd. raised its holdings in shares of ResMed by 32.2% during the fourth quarter. Invesco Ltd. now owns 2,325,009 shares of the medical equipment provider's stock valued at $531,706,000 after acquiring an additional 566,046 shares during the period. Norges Bank acquired a new stake in shares of ResMed during the fourth quarter valued at approximately $118,605,000. Los Angeles Capital Management LLC raised its holdings in shares of ResMed by 60.0% during the fourth quarter. Los Angeles Capital Management LLC now owns 668,908 shares of the medical equipment provider's stock valued at $152,973,000 after acquiring an additional 250,746 shares during the period. Proficio Capital Partners LLC acquired a new stake in shares of ResMed during the fourth quarter valued at approximately $50,364,000. Finally, Nordea Investment Management AB raised its holdings in shares of ResMed by 92.7% during the fourth quarter. Nordea Investment Management AB now owns 448,151 shares of the medical equipment provider's stock valued at $103,214,000 after acquiring an additional 215,561 shares during the period. Institutional investors and hedge funds own 54.98% of the company's stock.

Insider Buying and Selling

In related news, insider Kaushik Ghoshal sold 9,113 shares of the business's stock in a transaction dated Monday, March 3rd. The stock was sold at an average price of $235.40, for a total transaction of $2,145,200.20. Following the completion of the transaction, the insider now owns 9,725 shares of the company's stock, valued at approximately $2,289,265. The trade was a 48.38 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Peter C. Farrell sold 2,000 shares of the business's stock in a transaction dated Wednesday, February 5th. The stock was sold at an average price of $242.11, for a total value of $484,220.00. Following the transaction, the director now directly owns 77,218 shares of the company's stock, valued at $18,695,249.98. This represents a 2.52 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders sold 49,013 shares of company stock valued at $11,298,816. Insiders own 0.71% of the company's stock.

ResMed Price Performance

Shares of NYSE:RMD opened at $235.79 on Monday. ResMed Inc. has a fifty-two week low of $179.42 and a fifty-two week high of $263.05. The business has a 50-day moving average of $221.92 and a two-hundred day moving average of $234.00. The stock has a market capitalization of $34.63 billion, a P/E ratio of 27.84, a P/E/G ratio of 1.53 and a beta of 0.75. The company has a debt-to-equity ratio of 0.13, a current ratio of 3.33 and a quick ratio of 2.29.

ResMed (NYSE:RMD - Get Free Report) last announced its quarterly earnings results on Wednesday, April 23rd. The medical equipment provider reported $2.37 earnings per share for the quarter, hitting analysts' consensus estimates of $2.37. ResMed had a return on equity of 26.17% and a net margin of 25.34%. The company had revenue of $1.29 billion during the quarter, compared to analysts' expectations of $1.28 billion. On average, equities research analysts predict that ResMed Inc. will post 9.47 EPS for the current fiscal year.

ResMed Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, June 12th. Investors of record on Thursday, May 8th will be given a dividend of $0.53 per share. The ex-dividend date is Thursday, May 8th. This represents a $2.12 annualized dividend and a dividend yield of 0.90%. ResMed's dividend payout ratio is presently 23.79%.

Wall Street Analyst Weigh In

RMD has been the topic of a number of recent analyst reports. StockNews.com lowered shares of ResMed from a "buy" rating to a "hold" rating in a report on Thursday. JPMorgan Chase & Co. boosted their price target on shares of ResMed from $286.00 to $290.00 and gave the company an "overweight" rating in a report on Thursday. UBS Group cut their price objective on ResMed from $290.00 to $285.00 and set a "buy" rating for the company in a report on Thursday. KeyCorp set a $274.00 target price on ResMed in a research note on Thursday. Finally, Citigroup upgraded ResMed from a "neutral" rating to a "buy" rating in a research note on Wednesday, March 5th. One investment analyst has rated the stock with a sell rating, six have assigned a hold rating, eight have assigned a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and an average price target of $258.83.

About ResMed

ResMed Inc develops, manufactures, distributes, and markets medical devices and cloud-based software applications for the healthcare markets. The company operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including ApneaLink Air, a portable diagnostic device that measures oximetry, respiratory effort, pulse, nasal flow, and snoring; and NightOwl, a portable, cloud-connected, and disposable diagnostic device that measures AHI based on derived peripheral arterial tone, actigraphy, and oximetry over several nights.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.